NEW YORK, July 16-The Indiana Proteomics Consortium will be headed by longtime biotech manager John Hurrell, the consortium said yesterday.
Hurrell will help structure the new consortium by overseeing investigators and developing a management infrastructure.
He was most recently general manager of North Carolina's TriPath Oncology. Prior to that he was president and CEO of FluorRx, which he co-founded after leaving Boehringer Mannheim.
Indiana University, Purdue University and Eli Lilly jointly founded the consortium in February 2002 in order to develop new tools and techniques in proteomics.
Rick Ludwig, the consortium's interim director, will soon return to his work coordinating proteomics research at Lilly.